Background: Mast cell activation syndrome (MCAS), a recently recognized nonneoplastic mast cell disease driving chronic multisystem inflammation and allergy, appears prevalent and thus important. We report the first systematic characterization of a large MCAS population.
INTRODUCTION

F
or the nearly 150 years since discovery of the mast cell (MC) and the first disease associated with the MC (urticaria pigmentosa, the most common form of cutaneous mastocytosis), the spectrum of MC disease has been thought to be comprised principally of rare, neoplastic mastocytosis (both cutaneous mastocytosis and systemic mastocytosis [SM] ) and common, benign, allergic-type phenomena of inappropriate MC activation (e.g., allergy, urticaria, angioedema and anaphylaxis). With recent recognition that inappropriate MC activation is the unifying feature in all MC-driven diseases, there has been both a renaming of the spectrum as "MC activation disease" (MCAD) and new definition of "MC activation syndrome" (MCAS) featuring chronic, inappropriate, nonneoplastic MC activation resulting in multisystem inflammatory and allergic phenomena not fitting other defined allergic or inflammatory diseases. 1 The role of the MC in allergy has long been widely appreciated, but its many critical roles in inflammation too 2 have perhaps emerged "under the radar." It is becoming increasingly clear that MCAD (the bulk of which is likely MCAS) is a vast collection of diseases featuring different patterns of both aberrant constitutive MC mediator expression and aberrant MC reactivity. It is also becoming increasingly clear that MCs may be activated in both immunologic (e.g., immunoglobulin E-mediated) and nonimmunologic (e.g., mediated by cytokines such as corticotropin releasing hormone and substance P) manners. There have been various MCAD classification proposals, some proposing basic categories of primary (clonal), secondary (reactive) and idiopathic, 1 and others proposing each case is a relatively unique variant in a complex space (likely driven in most cases by heterogeneous profiles of mutations across many MC regulatory elements (genes, microRNAs, etc.
3 ) featuring multiple axes of MC misbehavior including axes of inappropriate activation plus an axis of neoplasticity. 4 Though suggested by preliminary research to possibly be epidemically prevalent, 5, 6 MCAS is difficult to clinically recognize for many reasons including its novelty, its complex multisystem presentations and the great heterogeneity of such presentations, this latter aspect thought, again, to be chiefly due to great underlying MC mutational heterogeneity. Although described in various limited fashions in the past decade in case reports, 7, 8 a patient symptom survey 9 and a few small series, 10, 11 MCAS has not yet been comprehensively characterized. Presented here is the first systematic objective characterization of a large population of adult patients with MCAS. plasma heparin, [16] [17] [18] urinary prostaglandin D 2 , 15, 16 urinary N-methylhistamine, 19, 20 urinary leukotriene E4 21, 22 and urinary 11-β-prostaglandin-F 2α 15, 16 ] or increased MCs identified in extracutaneous tissue), 23 and all of these diagnoses were made at age 16 or older. For purposes of follow-up, data cutoff was June 30, 2014. Patient demographics, comorbidities, symptoms and physical examination and laboratory test findings were abstracted by author L.B.A. from the entirety of the subjects' available records. Comorbidities and physical examination findings were all physiciandiagnosed; symptoms were all reported by patients either spontaneously or on review of systems. To account for different normal ranges in different assays used over time for any given laboratory parameter, each laboratory test result was normalized with respect to the assay's stated reference range and with an assumption that the reference range encompassed 2 standard deviations greater than and less than the range's midpoint. Descriptive statistics were used to characterize each examined parameter.
In the prospective population, blood samples were obtained for flow cytometry for established markers and for serologic assessment of putative markers of MC disease. Flow cytometric studies sought cells coexpressing CD45 and CD117 plus CD25 or CD2; 24 all such studies were performed on a single multicolor flow cytometer and interpreted by a single investigator (S.S.). To investigate potential drivers of the mild monocytosis frequently seen in MCAS, 25 serum levels of monocyte colony stimulating factor (M-CSF), granulocytemacrophage colony stimulating factor (GM-CSF), interleukin 3 and tumor necrosis factor alpha (TNF-α)-all known key monocyte growth factors and known MC products 14, [26] [27] [28] -were assessed using ELISA kits from RayBiotech, Inc. (Norcross, GA). All assays were performed by a single investigator (J.L.) per the manufacturer's instructions using kit-provided negative and positive controls.
RESULTS
Most (69%) of the 413 patients in this study were female; 75% were white, with virtually all of the rest African American. Median age at time of self-reported symptom onset was 9 years (range: 0-88). Median age at time of diagnosis was 49 years (range: Although most of the patients (72%) appeared chronically ill at some point, in general the studied patients appeared healthier than would be expected from their litanies of complaints (e.g., presenting with an objectively normal-for-age extent of hair despite complaint of excessive hair loss), likely contributing to a primary psychiatric diagnosis (especially anxiety, depressive, somatoform or conversion disorders) experienced by most at one or more points in their extensive prior evaluations. Many patients stated they had "learned to live" with their symptoms and often no longer reported certain symptoms unless specifically asked.
As previously reported for the retrospective subset, 25 general laboratory abnormalities in these patients with MCAS were common but typically modest in degree (i.e., only slightly above or below the upper or lower limit of normal, respectively) and thus less commanding of attention when viewed as isolated results rather than recurrent findings. Summaries of abnormalities found in routine blood count testing and routine chemistry testing in the entire study population are shown in Table 5 . Hematologic abnormalities typically had persisted at least 10 years before diagnosis of MCAS; chemistry abnormalities typically had persisted at least 6 years before diagnosis. Summaries of MC mediator levels determined in diagnostic testing are shown in Table 6 .
Across the entire prospectively accrued subpopulation, flow cytometric studies (methods detailed in Online Supplementary Table S5) failed to identify any cells expressing the targeted established signature of clonal MC disease. Furthermore, serum levels of M-CSF, GM-CSF, interleukin 3 and TNF-α were assessed and, despite finding expected values on negative and positive control samples, were not found elevated in any of the subjects. TNF-α was assessed, once or more, in the clinical laboratory in 15 of the 413 patients (8 in the retrospective population and 7 in the prospective population) and found to be elevated at least once in 7 of the 15 patients (47%), including 3 of the prospective subjects. Given our finding of expected results from positive controls, it is unclear why results of our TNF-α assay did not corroborate with the elevated TNF-α level found in at least these 3 prospective subjects. Different symptomatic states of the disease at time of clinical measurement versus time of research measurement may have led to these differences in levels.
As of follow-up cutoff, 388 patients (94%) were alive, 1 had been lost to follow-up and 24 patients (6%) had died of a wide array of causes (n ¼ 1 for each except as 
DISCUSSION
In analyses of comorbidities, symptoms and physical examination findings, this study well demonstrates the principally inflammatory nature of the polymorbidity resulting from MCAS. Comorbidities were defined as diagnoses established in the patients' medical record before diagnosis of MCAS; although verification of accuracy of these diagnoses was not possible, our data reflect the typically complex nature of patients who come to be diagnosed with MCAS. The multisystemic nature and long duration of symptoms in MCAS highlight the importance of obtaining a complete history in patients with mysterious chronic illness. In particular, it is easy to understand that a long duration of symptoms, together with the historical lack of recognition of MCAS as a potential explanation for such symptoms, can easily lead patients, out of futility, to cease reporting symptoms regardless of severity. Some patients even come to regard such symptoms as within the realm of "normal."
One of the authors (L.B.A.) has encountered multiple patients with MCAS, for example, who have suffered daily syncope for years and long since stopped reporting to their physicians; their first few years of such events taught them that death from the symptom was unlikely and no amount of evaluation was likely to provide a diagnosis, much less effective treatment. Only via a thorough review of systems can the clinician gain awareness of such symptoms.
Other interesting associations are seen, too, in these data. Treatment-refractory gastroesophageal reflux disease (GERD) may reflect undiagnosed MCAS. The preference of MCs for siting themselves not only at environmental interfaces but also at perivascular sites, and the presence of vasoconstriction-driving mediators such as renin among the vast MC mediator repertoire, 14 begs the question of whether some fraction of the essential hypertension population might be unrecognized MCAS. The author has seen MCAS treatment resolve otherwise refractory hyperlipidemia in some patients with MCAS, raising the question of what fraction of the hyperlipidemic population bears MCAS (perhaps 29, 30 Physicians (e.g., psychiatrists and emergency physicians) challenged by patients with recurrent idiopathic presentations of anxiety and panic might find more satisfying explanations for these problems in diagnostic assessments for MCAS. Sleep apnea, almost always obstructive, is found in 15% of patients with MCAS and curiously occurs not uncommonly in nonobese patients, raising questions of mechanisms which might include airways narrowed by edema, hypertrophy, fibrosis or excessive mucus, or excessive loss of airway muscular tone in sleep. Ehlers-Danlos syndrome (EDS) type III is present in 4% of this cohort, of interest not only because it is the far dominant type of EDS (40% of all EDS cases) but also because it is the only type of EDS for which a specific, highly recurrent mutational cause has not yet been identified. Given that MCs are integrally involved in regulation of growth and development in all tissues, the possibility is raised that some portion of the EDS-III population may bear a particular pattern of chronic MC mediator misexpression being driven by a particular set of mutations in MC regulatory elements. The connective tissue proteins themselves may be normal, but if the normal assembly of such proteins into healthy connective tissue is disturbed by chronic incorrect signaling from MCs, healthy connective tissue should not be expected.
As there remains contention regarding diagnostic criteria for MCAS, the recent update to the World Health Organization consensus criteria for diagnosing MC disease makes no statement regarding MCAS. 31 Of the 2 proposals in the literature for diagnostic criteria for MCAS during the period of our study, 23, 32 we feel (from experience in 41,000 patients) the criteria by Molderings et al 23 used to identify patients for this study better fit the behavior of the disease. We disfavored the criteria by Valent et al 32 for several reasons discussed previously in the literature 33 including (1) nonrecognition of many of the symptoms of MC activation, (2) lack of published validation that the suggested diagnostic tryptase calculation reliably distinguishes ordinary baseline fluctuation of tryptase from fluctuation induced by aberrant MC activation, (3) practical difficulties in providing or obtaining a specimen for serum total tryptase shortly after exacerbation of symptoms and (4) practical difficulties in finding-in such a heterogeneous disease -effective treatment before diagnosis. A slightly modified version of the criteria by Valent et al, 32 allowing wider ranges of MC activation symptoms and markers of MC activation than in the criteria by Valent et al 32 was recently proposed. 34 The frequencies of assorted symptoms in our MCAS cohort were generally consistent with earlier reports in both a general MCAD population (n ¼ 420; mastocytosis 75% and MCAS 12%) 9 and a small MCAS population (n ¼ 18), 11 underscoring the new understanding that aberrant MC activation, and the symptoms resulting therefrom, is the unifying feature of most MC disease. In addition to showing the great expanse of inflammatory phenomena in MC disease, data in these 3 studies highlight the importance of recognizing the differential diagnostic consideration of MC disease in patients with neuropsychiatric symptoms. Differences among the studies (e.g., flushing in 31% of our patients versus 76% in the patients 9 ) may be due to different methods (e.g., objective examination and medical record review in our patients versus patient self-report 9 ), different definitions (e.g., some facial erythema may have been judged as flush rather than rash), different populations (mastocytosis was dominant 9 but absent in our cohort and in the cohort studied by Hamilton et al 11 ) or other factors. We note, too, that many of the frequencies of various findings in our cohort likely are underestimates given that most (72%) of our patients were assessed retrospectively. As such, assessments for specific findings during encounters, and reporting of those assessments in the clinical records, may not have been performed as rigorously in the retrospective population as in the prospective population. We expect a more rigorous, exclusively prospective assessment would yield higher frequencies for many, even most, of the parameters shown.
There has been increasing evidence of MC involvement in a variety of chronic inflammatory diseases (CIDs). 2, 35 For example, 40% of the U.S. population reports GERD symptoms, 36 and in many the problem is refractory to essentially complete suppression of gastric acid production, suggesting an inflammatory root to this discomfort that is sometimes more specifically diagnostically labeled as nonerosive or functional GERD. Our study adds to suspicions that specific variants of MCAS may underlie fractions of various, heretofore, idiopathic CIDs. Ultimately, though, proof of such will require, at a minimum, examination of a cohort of patients diagnosed with any given CID to identify not only the proportion of that population in which MCAS (per current diagnostic criteria) is detectable but also the proportion in which such disease is primary, that is, the proportion in which either MC-activating autoimmunity or mutations in MC regulatory elements driving constitutive MC activation or aberrant MC reactivity or both, is found. Identification of 1 or more specific mutational patterns in MCs in patients with any given CID may spur a fundamentally new avenue for investigations into mechanisms and therapeutics for that CID. It is noteworthy that even though the hematopoietic origin of MCs assures that mutations found in MCs must be present in (unknown, and likely highly variable) fractions of other types of peripheral blood mononuclear cells (PBMoCs), assessment of the whole PBMoC population for MCAS-driving mutations may be inadequate given that the fraction of the PBMoC population constituted by MCs is so small (0.02%) that mutational "signals" might be lost amid the background "noise" of normal sequence in the vast majority of PBMoCs (including normal MCs). Until the performance of peripheral blood MC sequencing versus PBMoC sequencing for detecting MCAS-driving mutations is better understood, prudently designed searches for such mutations should probe both the general unselected PBMoC population and the isolated peripheral blood MC population in each subject.
Chronic inflammation is known to be a risk factor for malignancy. The data in this study suggest that the families of patients with MCAS bear various cancers at much higher rates than the general population, raising the question of whether MCAS underlies significant portions of the populations with at least some types of cancer. The outcome of cancer treatment has long been recognized to improve when comorbid mastocytosis is recognized and concurrently treated. 37 The data in this study suggest it may behoove oncologists to more commonly consider a comorbidity of MCAS when chronic multisystem inflammation and other symptoms more consistent with MC activation than cancer (e.g., syncope in nonmetastatic breast cancer) are present in any given patient with cancer.
The data in this study show that many parameters in "routine labs" are abnormal (e.g., elevations in red cell parameters, monocytes, eosinophils, basophils, transaminases or alkaline phosphatase), typically to a modest degree, for many years before diagnosis of MCAS. (In particular, we note that elevations in eosinophils are seen in many CIDs in which there have been growing suspicions of critical MC involvement, 38 raising questions of whether idiopathic eosinophilia by itself might become a useful marker suggesting consideration of MCAS.) Modest laboratory abnormalities unsurprisingly are given short shrift by busy practitioners when an obvious cause is not apparent, but this study suggests the persistent, or at least frequent, presence of such abnormalities in the context of chronic multisystem inflammation perhaps should spark consideration of MCAS. The chronic presence of such quantitative abnormalities in the MCAS population raises the possibility of developing informatics-based methods by which automated analysis of laboratory results could result in messaging to clinicians providing an initial suggestion of diagnostic consideration of MCAS.
A few specific common laboratory abnormalities deserve further note. A nontrivial fraction of the population (8%) showed JAK2-wild-type polycythemia, observed by author L.B.A. to be associated with likelihood to symptomatically respond to low-dose imatinib 7, 8 (and other unpublished data). This finding raises the question of what portion of the roughly 2% of the polycythemia vera population showing wild-type JAK2 might be misrecognized MCAS. Mild microcytosis is common and is typically due to iron deficiency caused either by bleeding or malabsorption secondary to (likely MCAS-driven) duodenal inflammation or chronic iatrogenic achlorhydria or both from proton pump inhibitor therapy addressing chronic GERD. Mild macrocytosis, too, is common, raising the question of what portion of the half of myelodysplastic syndrome cases that are cytogenetically normal might be unrecognized MCAS. Similarly, the commonness of (again, typically mild) thrombocytopenia and thrombocytosis raises the question of what portions of the populations of patients diagnosed, respectively, with autoimmune thrombocytopenia purpura and "triple-negative" (i.e., wild-type JAK2, CALR and MPL) essential thrombocytosis might harbor unrecognized MCAS.
The relative utilities of various MC mediators tested in diagnostic assessments for MCAS were found in this study (at one institution) to be similar to another large cohort (at a separate institution) recently reported. 39 The present study provides further evidence that plasma heparin is the most useful marker of MC activation, followed closely by prostaglandin D 2 and chromogranin A. Chromogranin A levels, though, can be confounded by heart or renal failure, proton pump inhibitor use, or neuroendocrine cancer. In addition, other work has clarified the importance of continuous specimen chilling, including use of refrigerated centrifugation for plasma separation, when seeking plasma heparin levels. 39 Furthermore, our present study adds to evidence mounting in the past decade that the serum tryptase level-while still quite useful as an initial laboratory screen for MC neoplasia in mastocytosis-is a relatively poor indicator of MC activation, and old precepts that MC disease is unlikely when the serum tryptase level is normal can no longer stand. It is clear that mastocytosis is less likely when the serum tryptase level is less than the threshold of 20 ng/mL defined in the World Health Organization diagnostic criteria for SM (1 study found 30% of patients with indolent SM had serum tryptase levels o20 ng/mL 40 ), but there is at least some elevation in tryptase in virtually all patients with SM (96% 41 ). In contrast, only 62 (16%) of the 388 patients with MCAS in this study tested at least once for a serum tryptase level were found to have any elevation in this parameter, and only 15 (24%) of these 62 (or 3.9% of the overall population tested at least once for tryptase) showed at least 1 serum tryptase level 420 ng/mL. Tryptase was tested more than once in 88 patients, but in only 2 patients was the tryptase level found 420 ng/mL more than once. Clearly, serum tryptase at a normal level, or elevated to o20 ng/mL or perhaps even somewhat above this level, is insufficient to exclude MCAS. A rise in serum tryptase (over the level determined at an "asymptomatic" baseline, which may not exist) of 20% þ 2 ng/mL has been proposed as a discriminator for MCAS, 32 but no data supporting this proposal have been published.
Though not specifically designed to examine such, this study hints that survival in MCAS, as already clearly identified in indolent SM, 41, 42 may be equivalent to that of the general population despite the chronic morbidity of the disease. There are not yet any biomarkers for predicting effective treatments in the individual or for objectively assessing response; symptom selfassessment guides decisions to further pursue versus cease (at least for a time) trials of yet more of the many therapies shown helpful in various patients with MCAS. 43 Formal quality-of-life assessments are needed, but in the authors' experience, most patients appear able to eventually identify regimens that help them feel significantly better than their pretreatment baseline most of the time. It is unclear whether diagnosis and treatment of MCAS can reduce the cost of care of these patients.
The negative findings (at least as measured by ELISA) in our exploratory studies offer caution that the few cytokines we were able to assess likely are not integrally involved in production of the intermittent mild monocytosis or thrombocytosis not uncommonly seen in MCAS. As previously noted, the MC's repertoire of mediators is quite large, and there may be many other mediators which directly or indirectly drive these peripheral blood findings. It may be, too, that other methods of cytokine assessment (e.g., Luminex) might be more productive, perhaps warranting further study of the cytokines we targeted.
Finally, although the racial imbalance in the study population may be a consequence of the single center in which the study was conducted, the sex imbalance in the study population is notable, especially in contrast to a finding of sex balance in most analyses of mastocytosis patient populations. It is unclear whether the imbalance found in this study is a true biological phenomenon, perhaps a consequence of interactions between female sex hormones and their receptors on MCs and other cells, or whether it is the result of culturally based bias toward more women than men seeking care for the typically non-life-threatening, nondisabling, nondisfiguring symptoms of MCAS.
In conclusion, MCAS is a recently recognized, likely prevalent and important entity within the realm of MCAD. Its protean manifestation as chronic multisystem polymorbidity of generally inflammatory and allergic themes hides beneath a cover of extreme heterogeneity of clinical presentation (potentially due to extreme mutational heterogeneity in MC regulatory elements), contributing to significant delays in recognition, diagnosis and treatment, and yet most patients with MCAS, once diagnosed as such, can eventually find significantly helpful treatment. Appreciation by clinicians of the diversity of presentation of MCAS as described in this report may facilitate earlier diagnosis, all the more important given not only good prospects for identifying helpful therapy but also expected long survival in most.
